204 related articles for article (PubMed ID: 38369265)
1. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W; Liu Z; Liu T
Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
5. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061
[TBL] [Abstract][Full Text] [Related]
6. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
8. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
9. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
10. CANT1 serves as a potential prognostic factor for lung adenocarcinoma and promotes cell proliferation and invasion in vitro.
Yao Q; Yu Y; Wang Z; Zhang M; Ma J; Wu Y; Zheng Q; Li J
BMC Cancer; 2022 Jan; 22(1):117. PubMed ID: 35090419
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
12. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
14. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
15. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
16. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
17. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
[TBL] [Abstract][Full Text] [Related]
18. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma.
Zhou Q; Li D; Zheng H; He Z; Qian F; Wu X; Yin Z; Bao PT; Jin M
Thorac Cancer; 2021 Oct; 12(19):2526-2536. PubMed ID: 34453499
[TBL] [Abstract][Full Text] [Related]
20. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
